Placebo to triamcinolone acetonide

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Gout

Phase 3

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

CompletedNCT01029652

Novartis PharmaceuticalsAcute Gout

Start: 2009-12-31End: 2010-10-31Updated: 2014-01-30

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

CompletedNCT01080131

Novartis PharmaceuticalsAcute Gout

Start: 2010-03-31End: 2011-10-31Updated: 2014-01-30